Fig. 2

Expression profile, prognostic value and enrichment analysis of ALG3 and POMT2 in bladder cancer. A Expression profile of mannosyltransferase family members (ALG1-14, POMT1-2) in bladder cancer. B, C Expression of ALG3 in non-paired bladder cancer tissues using the GSE13507 data set (B) and GSE188715 data set (C) from the GEO database. D Expression of ALG3 in paired bladder cancer tissues using the TCGA–BLCA data set from the TCGA database. E, F Expression of POMT2 in non-paired bladder cancer tissues using the GSE13507 data set (E) and GSE188715 data set (F) from the GEO database. G Expression of POMT2 in paired bladder cancer tissues using the TCGA–BLCA data set from the TCGA database. H, I Kaplan–Meier survival curves showing overall survival based on ALG3 (H) and POMT2 (I) expression in bladder cancer. J uniCox regression analysis assessing the prognostic value of age, gender, stage, and ALG3 expression for bladder cancer survival, presented with p values and hazard ratios. K uniCox regression analysis assessing the prognostic value of age, gender, grade, and POMT2 expression for bladder cancer survival, presented with p values and hazard ratios. L multiCox regression analysis evaluating the prognostic value of age, gender, stage, and ALG3 expression as independent markers for bladder cancer survival, presented with p values and hazard ratios. M multiCox regression analysis evaluating the prognostic value of age, gender, grade, and POMT2 expression as independent markers for bladder cancer survival, presented with p values and hazard ratios. N, O Circle diagrams of GO enrichment analysis showing functional enrichment results of differentially expressed genes based on ALG3 (N) and POMT2 (O) expression, including biological processes, molecular functions, and cellular components. P Five GSEA enrichment results highlighting ALG3-related pathways associated with cancer development and progression, including ROS, glycolysis, DNA repair, G2/M checkpoint and inflammatory response. Q Five GSEA enrichment results of POMT2-related pathways associated with cancer development and progression, including EMT, G2/M checkpoint, hypoxia, inflammatory response and KRAS activation. *P < 0.05, **P < 0.01, ***P < 0.001